In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …

BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this
tumor type on the basis of prognostic and predictive implications. BRAF alterations in …

Simple Summary The BRAFV600E mutation accounts for 8–10% of metastatic colorectal
cancer (mCRC) patients and it is an established prognostic factor. Median overall survival of …

Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …

Between 8% and 12% of patients with metastatic colorectal cancer (mCRC) harbor a BRAF-
V600E mutation in their tumors, which is associated with a poor response to standard …

Simple Summary Given that most patients with MSS mCRC do not respond to
immunotherapy agents or do not have durable clinical responses, there is an unmet clinical …

Simple Summary A subset of colorectal cancers (CRCs) is characterized by a mismatch
repair deficiency that is frequently associated with microsatellite instability (MSI). The …

Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer
(CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK …

The introduction of checkpoint inhibitors provided remarkable achievements in several solid
tumors but only 5% of metastatic colorectal cancer (mCRC) patients, ie, those with bearing …